BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cellnovo Receives CE Mark Approval for World's First Mobile Diabetes Management System


9/19/2011 8:00:39 AM

September 19, 2011, London, UK. Press Dispensary -- Cellnovo today announced that it has received CE Mark approval for the world’s first mobile diabetes management system, a significant milestone for the company and for people living with diabetes.

“This is Cellnovo’s first step in a journey to bring this mobile diabetes management system to the world,” says William McKeon, Chief Executive Officer of Cellnovo.

Cellnovo is a complete diabetes management system built around the principles of mobile, wireless technology. The system includes an insulin patch pump, a wireless, touch screen handset with a built-in blood glucose monitor, and an extendable applications set.

“Cellnovo has created the first insulin pump that brings innovation and combines form with function, essential qualities in a device that patients have to interact with 24/7,” says Dr. Pratik Choudhary, Clinical Lecturer in Diabetes at King’s College London.

Cellnovo’s ground breaking technology means that diabetes therapies can now be managed more easily, accurately and intuitively. The patch pump is the smallest and most precise ever developed, and the touch screen, wireless handset is instantly familiar to those who have used other mobile devices such as Apple’s iPhone.

“Cellnovo has combined advanced mobile and medical technology which may create a paradigm shift in diabetes care,” says Irl B. Hirsch, Professor of Medicine, University of Washington, Seattle, USA. “For the multitude of patients who could benefit from pump therapy, Cellnovo could be a game-changer.”

The most exciting feature of the Cellnovo handset is that it wirelessly receives and transmits real-time data to a portal for patients and caregivers to use. This means that patients no longer have the burden of keeping meticulous journals, and that the data collected is incredibly accurate and consistent, ensuring optimal monitoring and treatment of the disease.

“The ability to see real-time data of patients who may be hundreds of miles away provides the opportunity to redefine our care model,” says Dr. Mark Evans, Lecturer and Honorary Consultant at the Institute of Metabolic Science at the University of Cambridge.

About Cellnovo

Cellnovo, an innovative UK-based mobile health company, is committed to bringing greater freedom and ease-of-use to people living with diabetes. The company has developed the industry’s first mobile diabetes management system, which includes a patch pump, a mobile handset with a built-in blood glucose monitor, and an extendable applications set. For more information, please visit www.cellnovo.com.

FOR FURTHER INFORMATION PLEASE CONTACT

Bill McKeon, Chief Executive Officer

Cellnovo Ltd.

Tel: + 44 (0) 203 058 1250

Email: press@cellnovo.com

Site: www.cellnovo.com



Read at BioSpace.com

Cellnovo
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES